|
Delayed
Warsaw S.E.
10:14:23 04/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 6.390 PLN | -0.78% |
|
+5.62% | -3.18% |
| 08-03 | Molecure Receives Positive IDMC Recommendation To Continue The KITE Clinical Trial Without Changes To The Study Protocol | CI |
| 05-19 | Molecure Q1 net loss 4.1 mln zlotys | RE |
Turnover - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- MOC Stock
- Consensus Molecure S.A.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
